Mr. Stephen Kilmer reports

IMAGIN MEDICAL ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

Steven Chan has resigned from Imagin Medical Inc.'s board of directors for personal reasons and Chris Bleck has been appointed as Mr. Chan's successor, effective immediately.

"On behalf of everyone at Imagin, I would like to thank Steven for his many contributions to the company," said Dr. Robin A. Atlas, MD, chairperson of Imagin's board of directors. "I am also very pleased to welcome Chris to our team. He has extensive executive leadership experience, playing a critical role in developing corporate strategy and managing operations for both emerging and large companies in the global health care industry.

"The recent submission of a presubmission package marked the initiation of the FDA process for Imagin's i/Blue Imaging System, and Chris's diverse background working with companies in the medical device, diagnostic, nutrition and pharmaceutical industries should prove to be a tremendous asset to our board and to our shareholders as we move forward," added Dr. Atlas.

Mr. Bleck is an accomplished global health care industry veteran with over three decades of experience, including leading or being integrally involved with multiple clinical development programs, commercial product launches, public financings, licensing transactions, and mergers and acquisitions. Most recently, he served as the chief operating officer for OvaScience, a life science company focused on the discovery and development of novel treatments for infertility. His earlier experience includes senior management roles with Cytyc Corp. (now Hologic Inc.), Intact Medical Corp. (acquired by Medtronic PLC) and Incept BioSystems Inc. (acquired by ORIGIO a/s). Mr. Bleck began his career at Abbot Laboratories, where he held progressive positions over 18 years, including corporate vice-president of pediatric products and president of Abbott Canada. Mr. Bleck holds a BS in pharmacy and an MBA from the University of Connecticut.

About Imagin Medical Inc.

Imagin is developing powerful new imaging solutions for the detection and visualization of cancer. The company believes its technology will radically improve cancer care during minimally invasive procedures, improving the surgeon's ability to visualize, identify and remove cancerous cells. Imagin's initial target market is bladder cancer, the sixth most common cancer in the United States, and the costliest cancer to treat due to a greater than 50-per-cent recurrence rate. Developed at the Lawrence Livermore National Laboratory, Imagin's advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.

We seek Safe Harbor.